Get the Stockscreener App
3.87
1.78%
-0.07
Galectin Therapeutics Inc stock is traded at $3.87, with a volume of 99,681.
It is down -1.78% in the last 24 hours and down -1.02% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$3.94
Open:
$3.92
24h Volume:
99,681
Relative Volume:
0.46
Market Cap:
$390.29M
Revenue:
Net Income/Loss:
$-26.25M
P/E Ratio:
-9.4413
EPS:
-0.4099
Net Cash Flow:
$-20.05M
1W Performance:
+2.93%
1M Performance:
-1.02%
6M Performance:
+64.68%
1Y Performance:
-24.12%
1-Day Range:
$0.00
$0.00
1-Week Range:
$3.5101
$4.005
52-Week Range:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.87 | 390.29M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics stock gets a Phase 3 protocol update - AD HOC NEWS
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - The Manila Times
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - Yahoo Finance
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical - Seeking Alpha
Galectin Therapeutics seeks 250 million shares: what it means for Galectin Therapeutics stock - ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Galectin Therapeutics stock falls 2.22 percent as trial advances - AD HOC NEWS
Galectin Therapeutics stock holds a $399.36 million valuation - AD HOC NEWS
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Galectin Therapeutics stock holds steady as investors await next clinical updates - AD HOC NEWS
Galectin Therapeutics stock holds recent gains after phase 2b trial update - AD HOC NEWS
Galectin Therapeutics Inc. (GALT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III - Investing.com
Why Is Galectin Therapeutics (NASDAQ:GALT) Breaking Out Now? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us
Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research
Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review
Galectin (GALT) Q1 2026 Earnings: The EPS Result Is Below Expectation for the Current Session; Share Move - vinanet.vn
Galectin (GALT) Today: Posts a 5.43% Gain to $3.88 in the Current Update; Technical Setup: the Price Remains Bounded by the Supplied Support and Resistance on the DayTriple MA Cross - vinanet.vn
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight - PR Newswire UK
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusChart Pattern Alerts - dars.gov.et
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
3.04 |
16,250 |
49,400 |
16,250 |
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Sale |
5.13 |
16,250 |
83,284 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Option Exercise |
1.23 |
22,268 |
27,390 |
28,768 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Option Exercise |
2.50 |
47,467 |
118,668 |
47,467 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Sale |
5.04 |
47,467 |
239,234 |
0 |
| Harold Shlevin | Director |
Jun 29 '26 |
Proposed Sale |
5.04 |
22,268 |
112,212 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Sale |
5.04 |
22,268 |
112,231 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Sale |
5.00 |
7,732 |
38,660 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Option Exercise |
1.23 |
7,732 |
9,510 |
14,232 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Option Exercise |
2.37 |
4,570 |
10,814 |
2,533 |
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):